Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma
Source abstract
Abstract
Despite advances in neuroscience cancer research during the past decades, the survival of cancer patients has only marginally improved and the cure remains unlikely. The blood-brain barrier (BBB) is a major obstacle protecting the entry of therapeutic agents to central nervous system, especially for primary central nervous system lymphoma (PCNSL). Thus, the use of small nanoparticle as a drug carrier may be new strategies to overcome this problem. In this study, we fabricated liposome consisting of superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with anti-CD20 (Rituximab; RTX). The designed nanoparticles have a theranostic property which is not only to improve drug delivery, but also to offer diagnostic and monitoring capabilities. TEM images revealed the spherical shape of liposome with the approximately average diameters about 140-190nm with slightly negatively charge surfaces. Superparamagnetic property of SPIONs-loaded liposomes was confirmed by VSM. Liposome colloidal could be prolonged at 4°C and 25°C storages. RTX conjugated liposome induced cell internalization and apoptosis effect in B-lymphoma cells. Drug targeting and therapeutic effect was investigated in BBB model. The result confirmed that liposome nanocarrier is required as a drug carrier for effectively RTX across the BBB.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Glioma Diagnosis and Treatment · Lanthanide and Transition Metal Complexes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Primary brain tumours in adults10.1016/S0140-6736(03)12328-8 ↗
2. Neurological complications in AIDS patients receiving HAART: a 2‐year retrospective study10.1111/j.1468-1331.2006.01178.x ↗
3. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma10.1002/cncr.10851 ↗
4. Pathway analysis of primary central nervous system lymphoma10.1182/blood-2007-10-119099 ↗
5. Primary CNS lymphoma10.1200/JCO.2005.04.8819 ↗
6. Successful long-term control of lymphomatous meningitis with intraventricular rituximab10.1016/j.jocn.2013.03.033 ↗
7. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation10.1212/01.wnl.0000300671.37279.0e ↗
8. Rituximab monotherapy for patients with recurrent primary CNS lymphoma10.1212/WNL.0b013e31820f2d94 ↗
9. Blood–brain barrier models and their relevance for a successful development of CNS drug delivery systems: a reviewm10.1016/j.ejpb.2014.03.012 ↗
10. The need for new approaches in CNS drug discovery: why drugs have failed, and what can Be done to improve outcomes10.1016/j.neuropharm.2016.03.021 ↗
11. Nanoparticulate systems for brain delivery of drugs10.1016/S0169-409X(00)00122-8 ↗
12. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine10.1021/ar200105p ↗
13. A novel micelle-forming material used for preparing a theranostic vehicle exhibiting enhanced in vivo therapeutic efficacy10.1021/jm501996y ↗
14. Polyvalent folate-dendrimer-coated iron oxide theranostic nanoparticles for simultaneous magnetic resonance imaging and precise cancer cell targeting10.1021/acs.biomac.6b01885 ↗
15. Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain10.2310/7290.2011.00032 ↗
16. Liposomes and nanotechnology in drug development: focus on neurological targets10.2147/IJN.S30721 ↗
17. CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke10.1016/j.brainres.2005.07.067 ↗
18. Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia10.1016/j.ijpharm.2010.12.014 ↗
19. Liposomal drug product development and quality: current US experience and perspective
20. Transferrin-modified liposome promotes α-mangostin to penetrate the blood–brain barrier10.1016/j.nano.2015.10.021 ↗
21. Neuroprotection against degeneration of SK-N-MC cells using neuron growth factor-Encapsulated liposomes with surface cereport and transferrin10.1002/jps.24081 ↗
22. Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin10.1016/j.biomaterials.2014.03.082 ↗
23. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery10.1016/j.ejps.2010.03.007 ↗
24. Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting10.2147/IJN.S23771 ↗
25. Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study10.1021/mp300272a ↗
26. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues10.1038/nnano.2016.168 ↗
27. Effects of PVA-coated nanoparticles on human T helper cell activity10.1016/j.toxlet.2016.01.003 ↗
28. Effect of cell media on polymer coated superparamagnetic iron oxide nanoparticles (SPIONs): colloidal stability, cytotoxicity, and cellular uptake studies10.1016/j.ejpb.2007.02.024 ↗
29. Oxidative stress and dermal toxicity of iron oxide nanoparticles in vitro10.1007/s12013-012-9367-9 ↗
30. The blood–brain barrier permeability of geissoschizine methyl ether in Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansan10.1007/s10571-011-9676-3 ↗
31. Superparamagnetic silica-Iron oxide nanocomposites for application in hyperthermia10.1002/adem.200300574 ↗
32. Preparation and evaluation of sterically stabilized liposomes: colloidal stability, serum stability, macrophage uptake, and toxicity10.1002/jps.2600790803 ↗
33. Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model10.1371/journal.pone.0032568 ↗
34. Doxorubicin loaded PVA coated iron oxide nanoparticles for targeted drug delivery10.1016/j.msec.2010.01.006 ↗
35. Facile synthesis of monodispersed silica-coated magnetic nanoparticles10.1016/j.jiec.2013.12.014 ↗
36. Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics10.1517/17425247.2013.747507 ↗
37. Recent progress on magnetic iron oxide nanoparticles: synthesis, surface functional strategies and biomedical applications10.1088/1468-6996/16/2/023501 ↗
38. superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (sPION–egF) for targeting brain tumors10.2147/IJN.S55118 ↗
39. CD20-mediated apoptosis: signalling through lipid rafts10.1046/j.1365-2567.2002.01495.x ↗
40. Analyses of CD20 monoclonal antibody–mediated tumor cell killing mechanisms: rational design of dosing strategies10.1124/mol.114.092684 ↗